Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.50M | 4.71M | 5.07M | 4.49M | 7.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.50M | 4.71M | 5.07M | 4.49M | 7.41M |
| Cost of Revenue | 12.39M | 11.84M | 10.38M | 10.57M | 9.30M |
| Gross Profit | -7.89M | -7.13M | -5.31M | -6.08M | -1.89M |
| SG&A Expenses | 4.78M | 4.71M | 4.93M | 4.96M | 4.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.16M | 16.54M | 15.31M | 15.52M | 14.06M |
| Operating Income | -12.66M | -11.84M | -10.24M | -11.04M | -6.65M |
| Income Before Tax | -12.62M | -11.79M | -10.18M | -10.97M | -6.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.62 | -11.79 | -10.18 | -10.97 | -6.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 500.00 | 500.00 | 500.00 | 200.00 | 200.00 |
| Net Income | -12.62M | -11.79M | -10.18M | -10.97M | -6.58M |
| EBIT | -12.66M | -11.84M | -10.24M | -11.04M | -6.65M |
| EBITDA | -8.91M | -6.34M | -2.78M | -- | -- |
| EPS Basic | -2.76 | -3.35 | -4.22 | -6.37 | -4.07 |
| Normalized Basic EPS | -1.72 | -2.09 | -2.64 | -3.98 | -2.55 |
| EPS Diluted | -2.76 | -3.35 | -4.22 | -6.37 | -4.07 |
| Normalized Diluted EPS | -1.72 | -2.09 | -2.64 | -3.98 | -2.55 |
| Average Basic Shares Outstanding | 26.45M | 15.62M | 10.18M | 7.72M | 5.49M |
| Average Diluted Shares Outstanding | 26.45M | 15.62M | 10.18M | 7.72M | 5.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |